The global biosimilar contract manufacturing market is projected to be valued at US$ 10.70 billion in 2024. Biosimilars are biological therapeutics which are highly similar to an already approved biological reference product. Manufacturing biological drugs and biosimilars require specialized equipment and manufacturing capacities. Contract manufact